Company Description
Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States.
The company's lead product candidate is the ADG20 (adintrevimab), a neutralizing antibody that is in Phase 3 clinical trials for the treatment and prevention of coronavirus disease.
Adagio Therapeutics, Inc. has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses.
The company was incorporated in 2020 and is based in Waltham, Massachusetts.
| Country | United States |
| IPO Date | Aug 6, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 94 |
| CEO | Dr. Robert D. Allen Ph.D. |
Contact Details
Address: 1601 Trapelo Road Waltham, Massachusetts United States | |
| Website | https://adagiotx.com |
Stock Details
| Ticker Symbol | IVVD |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001832038 |
| CUSIP Number | 00534A102 |
| ISIN Number | US00534A1025 |
| Employer ID | 85-1403134 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Jill Andersen J.D. | Chief Legal Officer & Corporate Secretary |
| William E. Duke Jr., M.B.A. | Chief Financial Officer & Principal Executive Officer |
| Dr. Mark A. Wingertzahn Ph.D. | Senior Vice President of Clinical Development & Medical Affairs |
| Dr. Robert D. Allen Ph.D. | Chief Scientific Officer |
| Julie Green M.B.A. | Chief Human Resources Officer |
| Scott Young | Senior Vice President of Investor Relations & Corporate Communications |
| Stacy Price M.S. | Chief Technology & Manufacturing Officer |
| Timothy Lee | Chief Commercial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 31, 2024 | 4 | Filing |
| Dec 27, 2024 | 8-K | Current Report |
| Dec 26, 2024 | 4 | Filing |
| Dec 19, 2024 | 4 | Filing |
| Dec 16, 2024 | 4 | Filing |
| Dec 12, 2024 | SC 13D/A | [Amend] Filing |
| Dec 11, 2024 | 4 | Filing |
| Dec 02, 2024 | 8-K | Current Report |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |